Literature DB >> 12505801

Loss of striatal vesicular monoamine transporter protein (VMAT2) in human cocaine users.

Karley Y Little1, David M Krolewski, Lian Zhang, Bader J Cassin.   

Abstract

OBJECTIVE: The hypothesis that human cocaine users lose vesicular monoamine transporter (VMAT2) protein was tested in striatal samples from cocaine users and age-, sex-, and postmortem interval-matched comparison subjects.
METHOD: Striatal samples were retrieved at autopsy; immunoblot assays were then performed by using a highly specific VMAT2 antibody. Striatal radioligand binding to VMAT2 was assessed with dihydrotetrabenazine ([(3)H]DTBZ) and dopamine levels employing high-performance liquid chromatography.
RESULTS: Cocaine users displayed a marked reduction in VMAT2 immunoreactivity as well as reduced [(3)H]DTBZ binding and dopamine levels. It did not appear that the reduction in VMAT2 immunoreactivity was related to ethanol use, but dopamine levels were lower in subjects with only ethanol diagnoses. Subjects suffering from cocaine-induced mood disorders displayed a greater loss of VMAT2 immunoreactivity that approached significance.
CONCLUSIONS: Human cocaine users lose VMAT2 protein, which might reflect damage to striatal dopamine fibers. These neuronal changes could play a role in causing disordered mood and motivational processes in more severely dependent patients.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12505801     DOI: 10.1176/appi.ajp.160.1.47

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  26 in total

1.  A tyrosine-based motif localizes a Drosophila vesicular transporter to synaptic vesicles in vivo.

Authors:  Anna Grygoruk; Hao Fei; Richard W Daniels; Bradley R Miller; Aaron Diantonio; David E Krantz
Journal:  J Biol Chem       Date:  2010-01-06       Impact factor: 5.157

2.  Decreased vesicular monoamine transporter type 2 availability in the striatum following chronic cocaine self-administration in nonhuman primates.

Authors:  Rajesh Narendran; Hank P Jedema; Brian J Lopresti; Neale Scott Mason; Michael L Himes; Charles W Bradberry
Journal:  Biol Psychiatry       Date:  2014-06-23       Impact factor: 13.382

3.  Teaching about genetic testing issues in the undergraduate classroom: a case study.

Authors:  Jill Cellars Rogers; Ann T S Taylor
Journal:  J Genet Couns       Date:  2011-03-04       Impact factor: 2.537

4.  Cocaine, but not amphetamine, short term treatment elevates the density of rat brain vesicular monoamine transporter 2.

Authors:  K Schwartz; R Nachman; M Yossifoff; R Sapir; A Weizman; M Rehavi
Journal:  J Neural Transm (Vienna)       Date:  2006-08-08       Impact factor: 3.575

5.  What's deficient in reward deficiency?

Authors:  Marco Leyton
Journal:  J Psychiatry Neurosci       Date:  2014-09       Impact factor: 6.186

Review 6.  Glial modulators as potential treatments of psychostimulant abuse.

Authors:  Patrick M Beardsley; Kurt F Hauser
Journal:  Adv Pharmacol       Date:  2014

7.  Abstinence from chronic cocaine self-administration alters striatal dopamine systems in rhesus monkeys.

Authors:  Thomas J R Beveridge; Hilary R Smith; Michael A Nader; Linda J Porrino
Journal:  Neuropsychopharmacology       Date:  2008-09-03       Impact factor: 7.853

Review 8.  Striatal ups and downs: their roles in vulnerability to addictions in humans.

Authors:  Marco Leyton; Paul Vezina
Journal:  Neurosci Biobehav Rev       Date:  2013-01-16       Impact factor: 8.989

9.  VMAT1 deletion causes neuronal loss in the hippocampus and neurocognitive deficits in spatial discrimination.

Authors:  P K Multani; R Hodge; M A Estévez; T Abel; H Kung; M Alter; B Brookshire; I Lucki; A H Nall; K Talbot; G A Doyle; F W Lohoff
Journal:  Neuroscience       Date:  2012-11-29       Impact factor: 3.590

10.  Financial and psychological risk attitudes associated with two single nucleotide polymorphisms in the nicotine receptor (CHRNA4) gene.

Authors:  Brian E Roe; Michael R Tilley; Howard H Gu; David Q Beversdorf; Wolfgang Sadee; Timothy C Haab; Audrey C Papp
Journal:  PLoS One       Date:  2009-08-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.